Arch Biopartners Inc. announced that the Research Ethics Board at the Sunnybrook Research Institute has approved the amendment to the CATCO protocol to include its lead drug candidate, LSALT Peptide (LSALT and Metablok) in a new arm of the CATCO human trial. CATCO leadership will now seek Health Canada approval before commencing the dosing of LSALT in the new arm of the trial.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.16 USD | -2.53% | -4.92% | +3.90% |
06-27 | Arch Biopartners Up More Than 2% After Announcing GMP Manufacturing Of Cilastatin Drug Product | MT |
06-27 | Arch Biopartners Inc. Announces GMP Manufacturing of Cilastatin Drug Product | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.90% | 74.53M | |
+24.74% | 47.54B | |
-0.47% | 41.96B | |
+46.11% | 41.55B | |
+25.40% | 30.36B | |
+17.96% | 27.61B | |
-4.47% | 28.7B | |
+50.73% | 14.7B | |
+42.56% | 13.51B | |
+1.46% | 12.34B |
- Stock Market
- Equities
- ACHFF Stock
- News Arch Biopartners Inc.
- Arch Biopartners Inc. Announces Research Ethics Board Approves Amendment to Canadian Treatments for COVID-19 Trial to Include LSALT Peptide